Vanguard Capital Management
IBIO icon

Vanguard Capital Management’s iBio IBIO Stock Holding History

Vanguard Capital Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.67M Buy
2,098,151
+1,009,852
+93% +$1.81M ﹤0.01% 3224
2026
Q1 		$2.07M Buy
+1,088,299
New +$2.53M ﹤0.01% 3352

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Vanguard Capital Management's IBIO Position: Q2 2026 in Review

Vanguard Capital Management increased its iBio (IBIO) stake by 93% in Q2 2026, buying an estimated $1.81M and bringing the position to 2,098,151 shares worth $3.67M. The position accounts for ﹤0.01% of the portfolio, ranked #3224.

Vanguard Capital Management first reported a position in IBIO in Q1 2026 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Vanguard Capital Management held 2,098,151 shares of iBio worth $3.67M as of Q2 2026.
  • Vanguard Capital Management bought 1,009,852 iBio shares in Q2 2026, an estimated $1.81M.
  • iBio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3224 holding.
  • Vanguard Capital Management first reported a position in iBio in Q1 2026 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.